Team
At Recalivape, innovation is intentional, strategic, and interdisciplinary. Our leadership unites expertise across neuroscience, pharmacology, bioengineering, regulatory strategy, and entrepreneurial commercialization to reimagine addiction treatment for the modern era. By combining rigorous scientific research, clinical insight, regulatory mastery, and visionary business development, we are building a platform that redefines how society addresses substance dependence.
Farid Manshaii
Founder & CEO
Farid Manshaii is an interdisciplinary researcher and entrepreneur whose academic foundation spans neuroscience, bioengineering, psychology, and addiction pharmacology, cultivated through rigorous training at UCLA and Keck Graduate Institute. As the Founder and CEO of Recalivape, he applies his scientific expertise and systems thinking to pioneer adaptive health technologies, architect innovative solutions, and drive long-term societal impact that transcends conventional technological approaches.
Board of Advisors
Dr. Thomas Lobl
Scientific, Pharmaceutical, and Business Strategy Advisor
Dr. Thomas Lobl holds a Ph.D. from Johns Hopkins University and brings over four decades of leadership experience in the pharmaceutical and biotechnology sectors. He has held executive roles at MannKind, NeuroSystec, and the Alfred Mann Institute. A prolific inventor with over 74 publications and patents, Dr. Lobl provides Recalivape with strategic guidance in clinical development, therapeutic delivery systems, and business strategy, advancing both our scientific and commercial missions.
Dr. Edythe London
Clinical and Neuroscience Advisor
Dr. Edythe London is an internationally recognized neuroscientist and pharmacologist, currently serving as a distinguished professor at UCLA. Specializing in addiction research, she pioneers the use of advanced brain imaging technologies such as PET and fMRI to study substance use disorders. With over 300 published research articles, Dr. London ensures the clinical and scientific rigor of Recalivape’s research initiatives and guides the translational impact of our innovations.
Shepard Bentley
Regulatory Strategy Advisor
Shepard Bentley, President and Principal Consultant at Bentley Biomedical Consulting, LLC, is an expert in regulatory affairs for medical devices and pharmaceuticals. With over 30 years of experience, including successful leadership at Rising Star and Volcano Therapeutics, he advises Recalivape on FDA and Health Canada regulatory pathways, compliance frameworks, and strategic market entry initiatives, ensuring our technologies meet global standards for approval and adoption.
Jay Goth
Innovation and Commercialization Advisor
Jay Goth is a serial entrepreneur and innovation strategist with more than 40 years of cross-sector experience spanning genomics, energy, technology, and finance. As CEO of Burble Creativity Inc. and Founder of Redtail Capital, he specializes in scaling startups and driving strategic growth initiatives. Recognized as the 2016 SBA Small Business Champion of the Year, Jay provides Recalivape with critical expertise in commercialization strategies, startup development, and strategic fundraising.
Together, our leadership team combines deep scientific knowledge, clinical acumen, regulatory insight, and entrepreneurial vision—positioning Recalivape to lead the next generation of personalized, data-driven addiction treatment technologies.